AlphAIalphai — Financial news for AI agents
Stock TitanMAY 154 min read$DARE

Daré Bioscience (NASDAQ: DARE) details Q1 loss and 2026–27 revenue milestones

Daré Bioscience reported a Q1 2026 net loss of approximately $3 million on revenue of $152,455, primarily from R&D services and royalties. The company highlighted upcoming revenue milestones in 2026 and 2027 from product launches like Flora Sync LF5 and DARE to PLAY, while also advancing its pipeline with positive interim Phase 3 results for Ovaprene and ARPA-H funded DARE-HPV. Daré aims to build a multi-product revenue profile to complement its grant funding and equity financings.

Original reporting
Stock Titan
Published May 15, 2026, 2:10 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 15, 2026, 2:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$DARE
Neutral
medium confidence
Mentioned
$DARE
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$DARENeutralMed
01

Why it matters

Successful product launches and clinical milestones could significantly enhance valuation, but execution risks remain.

02

Market read

The company's upcoming milestones are relevant for investors interested in biotech growth prospects, especially in women's health.

03

What to watch

Potential delays in product launches, regulatory hurdles, or market competition could impact future performance.

Timing: High, given upcoming product launches and revenue milestones within 2026-2027.

Background

Daré Bioscience is advancing its pipeline with promising clinical results and upcoming product launches, aiming to diversify revenue streams beyond grants and equity funding.

Company-level read

Ticker impact

$DARENeutralMedium confidence
Context

Primary focus due to recent earnings report and upcoming revenue milestones.

Expected impact

Moderate positive impact in the medium term, contingent on successful product launches and pipeline advancements.

Evidence & confidence

The company's upcoming milestones and positive clinical results could lead to improved investor sentiment and potential stock appreciation, but the current net loss and limited revenue indicate caution.

Market effects

Sector

Potential positive influence on biotech and life sciences sectors, especially companies with similar product pipelines.

Regional

Limited, as Daré Bioscience operates primarily in the US market.

Global

Low, due to company-specific developments and limited international exposure.

Counterpoint

What could challenge this read

The company's losses and limited revenue suggest caution; positive clinical results may not translate into immediate stock gains.

Key entities

  • Product
    Ovaprene

    A contraceptive product with positive interim Phase 3 results.

  • Product
    Dare to Play

    Upcoming product expected to contribute to revenue milestones.

  • Company
    Dare Bioscience

    Biotech firm focusing on women's health and reproductive solutions.

Read at source← All news

Related articles

AUG 13
$DAREMed

Dare Bioscience, Inc. (DARE): Results of Operations and Financial Condition

Dare Bioscience, Inc. (DARE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances Company launches Flora Sync LF5™, the company’s first directly commercialized product, began generating revenue in July DARE to

SEC EDGAR 8-K7 min
SEP 4
$GDMedAI 9/10

General Dynamics wins $249m in US military contracts

General Dynamics (GD) won two U.S. military contracts totaling $248.9M. One is a $149.6M contract for USS Pinckney modernization, with potential value up to $149.9M. The other is a $99.3M task order for MUOS Ground Infrastructure Segment upgrades. Both contracts are sole-source and involve work through 2028, funded by fiscal 2026 budgets.

investing.com2 min
SEP 4
$LMTHighAI 9/10

Lockheed Martin wins $150 million in defense contracts

Lockheed Martin Corp received three contract modifications worth over $150 million from the U.S. Department of Defense. The largest, $90.2 million, is for the TRIDENT II Life Extension 2 program, with work spread across multiple locations. The other contracts, $40.1 million and $20.3 million, are for the MK 41 Vertical Launching System and HH-60W repairs, respectively. Completion dates range from 2027 to 2030.

investing.com2 min
SEP 4
$NVSMedAI 8/10

Novartis Pharma AG: Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

Novartis announced that the Phase III Lp(a)HORIZON trial for pelacarsen did not meet its primary endpoint of reducing cardiovascular events. The study, involving 8,323 patients, showed that while pelacarsen lowered Lp(a) levels, it did not reduce cardiovascular risk. Novartis obtained rights to pelacarsen from Ionis Pharmaceuticals. Elevated Lp(a) affects about 20% of people worldwide and has no approved targeted treatment.

finanznachrichten.de2 min